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Abstract Phenylalanine hydroxylase (PAH) is activated by its
substrate phenylalanine and inhibited by its cofactor tetrahy-
drobiopterin (BH4). The crystal structure of PAH revealed that
the N-terminal sequence of the enzyme (residues 19^29) partially
covered the enzyme active site, and suggested its involvement in
regulation. We show that the protein lacking this N-terminal
sequence does not require activation by phenylalanine, shows an
altered structural response to phenylalanine, and is not inhibited
by BH4. Our data support the model where the N-terminal
sequence of PAH acts as an intrasteric autoregulatory sequence,
responsible for transmitting the effect of phenylalanine activation
to the active site. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Phenylalanine hydroxylase (PAH, EC 1.14.16.1) is a meta-
bolic enzyme that converts phenylalanine to tyrosine using
molecular oxygen, enzyme-bound iron, and a 6R-tetrahydro-
biopterin (BH4) cofactor [1^5]. PAH is a member of the ar-
omatic amino acid hydroxylase family, together with tyrosine
hydroxylase (TH, EC 1.14.16.2) and tryptophan hydroxylase
(TPH, EC 1.14.16.4). TH and TPH are involved in the bio-
synthesis of the neurotransmitters, L-DOPA (dihydroxy-
phenylalanine) and serotonin, respectively. The aromatic ami-
no acid hydroxylases share a similar enzyme mechanism and
have a common three-domain structure consisting of an N-
terminal regulatory domain, a catalytic domain and a C-ter-
minal tetramerisation domain; the highest sequence and struc-
tural similarity is found in the catalytic domain [6].
The regulatory domains of the aromatic amino acid hy-
droxylases are not highly conserved, re£ecting the di¡erent
modes of regulation required by these enzymes. PAH controls
the level of phenylalanine, an essential amino acid, which is
toxic at pathophysiological levels and is subject to large £uc-
tuations due to dietary intake. Accordingly, mutations in the
PAH gene lead to the disease phenylketonuria [7]. PAH is
therefore by necessity tightly controlled by a variety of mech-
anisms, including activation by phenylalanine, inhibition by
BH4 and additional activation by phosphorylation [2]. Acti-
vation by the substrate phenylalanine is considered the major
regulatory event. Phenylalanine is proposed to bind coopera-
tively to either an allosteric site, physically distinct from the
catalytic site [8], or directly to the active site [9]. Phenylalanine
activation leads to large conformational changes as inferred
from an increase in tryptophan £uorescence [10], exposure of
a hydrophobic surface [8], and a change in susceptibility to
proteolysis [11].
The natural cofactor BH4 acts as a negative regulator. BH4
has been reported to block phenylalanine activation [12]
through binding to a site distinct from the BH4 catalytic
site, and forming an inactive BH4^PAH complex [13]. The
phenylalanine-activated PAH is not inhibited by BH4 [12].
Synthetic cofactors such as 6-methyl-5,6,7,8-tetrahydropterin
(6-MePH4) do not have this inhibitory e¡ect [12]. Finally,
phosphorylation by cAMP-dependent protein kinase at Ser-
16 [14] is believed to act as a mediator of phenylalanine acti-
vation by decreasing the phenylalanine concentration required
to activate the enzyme [15].
The only available three-dimensional structure of an aro-
matic amino acid hydroxylase that includes the regulatory
domain is that of a dimeric rat PAH lacking the C-terminal,
24-residue tetramerisation domain (PAH1ÿ428) [16]. The cata-
lytic properties of PAH1ÿ428 are indistinguishable from the
full-length enzyme [17], and it is similarly regulated by phenyl-
alanine [17], phosphorylation [18] and BH4 (this work). One
of the most interesting features of the structure of the regu-
latory domain is the location of the N-terminal sequence (ami-
no acids 19^29), which reaches into the active site of the
catalytic domain (Fig. 1). This sequence may consequently
autoinhibit the enzyme, acting as an intrasteric autoregulatory
sequence (IARS) [16,19]. However, the mechanism of the
autoinhibition is unclear, as the proposed binding sites for
pterin [20,21] and phenylalanine [22] would not be obstructed
by the IARS. Residues 1^18, containing the phosphorylatable
Ser-16, are mobile in both the phosphorylated and dephos-
phorylated forms of PAH1ÿ428 [16]. Nevertheless, the compar-
ison of the structure of PAH1ÿ428 [16] with the structures of
the constitutively active fragments lacking the regulatory do-
main [23,24] shows that there are no signi¢cant structural
di¡erences in the active site regions, suggesting that the regu-
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latory domain must be responsible for the regulation of PAH
activity.
To elucidate the role of the IARS in PAH regulation we
expressed a PAH protein lacking 29 N-terminal amino acids
(PAH30ÿ428) and characterised its regulatory properties. We
show that PAH30ÿ428 is constitutively active (i.e. it does not
require phenylalanine activation), shows an altered structural
response to phenylalanine, and is not negatively regulated by
BH4. Our results add functional support to the model previ-
ously suggested based on structural data, whereby the N-ter-
minal sequence is responsible for autoinhibition and for trans-
mitting the e¡ect of phenylalanine activation to the active site.
2. Materials and methods
2.1. Protein expression and puri¢cation
PAH30ÿ428 cDNA was cloned into the pKKT7 plasmid (ATCC,
USA [25]). Protein expression was induced at 30‡C for 5 h by the
addition of 0.4 mM isopropyl-1-thio-L-D-galactopyranoside. All puri-
¢cation procedures were carried out at 4‡C unless otherwise stated.
Cells were pelleted, frozen and thawed, resuspended in 0.05 M Tris^
HCl (pH 7.25), 10 mM phenylalanine, 0.1 mM EDTA (bu¡er 1)
containing 0.1 mg/ml phenylmethylsulfonyl £uoride, 0.4 Wg/ml pepsta-
tin and 0.4 Wg/ml leupeptin, and sonicated. The cell extract was cen-
trifuged at 27 200Ug for 20 min. The supernatant was puri¢ed by
ammonium sulphate precipitation (50% w/v). Following dialysis
against bu¡er 1, the protein was applied to a DE-52 cellulose column
and eluted with a linear gradient of 0^0.3 M KCl. The eluted peak
was dialysed against 50 mM Na2HPO4/NaH2PO4 (pH 7.0) containing
10% glycerol (bu¡er 2) and applied to a column (5 ml bed volume) of
Biogel HTP hydroxyapatite (Bio-Rad) equilibrated with bu¡er 2. Fol-
lowing a 50 ml wash with bu¡er 2, the protein was eluted with a linear
gradient of 50^350 mM Na2HPO4/NaH2PO4 (pH 7.0) containing 10%
glycerol. Fractions containing PAH30ÿ428 were pooled and dialysed
twice against 2 l of 30 mM Tris^HCl (pH 7.25), 0.15 M KCl and
0.1 mM EDTA. PAH1ÿ428 was expressed in insect cells and puri¢ed
using phenyl-Sepharose chromatography [18].
2.2. Limited proteolytic digestion
PAH was activated, where indicated, by incubation with 10 mM
phenylalanine for 10 min at 25‡C. Limited proteolytic digestion was
carried out by incubating PAH with chymotrypsin at an enzyme:pro-
tein ratio of 1:50 at 25‡C. Digestion was stopped by the addition of
an equal volume of a solution containing 4% (w/v) sodium dodecyl
sulphate (SDS), 30% glycerol (v/v) and 10% mercaptoethanol (v/v) in
10 mM Tris^HCl (pH 6.8) and heating at 90‡C for 5 min. Samples
were then analysed on a 12% polyacrylamide gel containing 0.1%
(w/v) SDS (SDS^PAGE).
2.3. Enzyme activity assay
To measure enzyme activity, PAH was added last to a cuvette
containing 100 mM K2HPO4/KH2PO4 (pH 6.8), 65 Wg/ml catalase,
2.75 mM phenylalanine, 6 mM dithiothreitol and either 60 WM
6-MePH4 or 90 WM BH4 (Schirck’s Laboratories, Jona, Switzerland),
at 20‡C. Activity was estimated by measuring the absorbance change
at 275 nm over the initial 60 s of the reaction with the activity ex-
pressed as nmol of tyrosine produced/min, using an extinction coef-
¢cient for tyrosine of 1700. Because PAH1ÿ428 and PAH30ÿ428 are
di¡erent protein preparations, the absolute activity values should
not be directly compared.
3. Results
3.1. Cloning and expression of the PAH30ÿ428 protein
The DNA coding for the PAH30ÿ428 protein was expressed
in Escherichia coli, and puri¢ed by ammonium sulphate pre-
cipitation, ion exchange chromatography and hydroxyapatite
chromatography. The puri¢ed PAH30ÿ428 protein has the ex-
pected MW of 46 kDa as analysed by SDS^PAGE (Fig. 2).
N-terminal protein sequencing of puri¢ed PAH30ÿ428 gener-
ated the expected amino acid sequence (data not shown).
3.2. Activation by phenylalanine
The extent of activation by phenylalanine was assayed by
adding unactivated PAH or PAH activated by 10 mM phenyl-
alanine to a cuvette containing all the other components suf-
¢cient for PAH enzyme activity (Table 1). In the presence of
the synthetic cofactor 6-MePH4, phenylalanine activation of
PAH1ÿ428 resulted in a four-fold increase in kcat ; the removal
of the N-terminus (PAH30ÿ428) decreased the phenylalanine
activation to two-fold. In the presence of the natural cofactor
BH4, phenylalanine activation of PAH1ÿ428 expectedly pro-
duced a more prominent 12.5-fold increase in kcat. By con-
trast, phenylalanine activation of PAH30ÿ428 had little e¡ect
(1.1-fold activation). Thus, in the presence of BH4 the remov-
al of the N-terminus produced a constitutively active enzyme
with little or no requirement for phenylalanine activation.
3.3. Inhibition by BH4
The e¡ect of the removal of the IARS on BH4 inhibition
Fig. 1. The interaction of the IARS with the PAH active site. A rib-
bon diagram of the structure of a PAH monomer (PDB code 1PHZ
[16]) is shown with the IARS (Gly-19 to Gln-30) in dark grey, and
the side chains of Ser-23, Tyr-24 and Ile-25 interacting with the ac-
tive site are indicated in a ball-and-stick representation. For orienta-
tion purposes only, the proposed positions of the substrate phenyla-
lanine (Phe), and the pterin inhibitor, 7,8-dihydrobiopterin (BH2),
are shown based on the model of Teigen et al. [22].
FEBS 24513 12-1-01
I.G. Jennings et al./FEBS Letters 488 (2001) 196^200 197
was assessed by assaying at BH4 concentrations below those
required for catalysis but su⁄cient for PAH inhibition, and
using 6-MePH4 as the cofactor in the PAH assay (6-MePH4 is
not a PAH inhibitor) [13] (Table 2). Enzyme activity of
PAH1ÿ428, which under these experimental conditions re£ects
phenylalanine activation, was signi¢cantly decreased (by 64%)
in the presence of BH4. By contrast, no BH4 inhibition was
observed for PAH30ÿ428, lacking the N-terminal IARS.
3.4. Limited chymotryptic digestion and hydrophobic
interaction chromatography
Upon limited chymotryptic digestion, a 31-kDa fragment is
generated from phenylalanine-activated PAH1ÿ428, that has
previously been shown [26] to correspond to the catalytic
domain of PAH (amino acids 120^424) (Fig. 2A). Unactivated
PAH1ÿ428 is more resistant to chymotryptic digestion; less
catalytic fragment accumulates. In phenylalanine-activated
PAH30ÿ428, the generation of the catalytic fragment is slowed
down when compared to PAH1ÿ428 (Fig. 2B). It is reassuring
that only subtle di¡erences are observed in the proteolytic
patterns, suggesting no major structural perturbations in the
truncated protein.
Previously, both the full-length phenylalanine-activated
PAH [8] and the phenylalanine-activated PAH1ÿ428 [17] have
been shown to bind to phenyl-Sepharose and could subse-
quently be eluted from the resin by a phenylalanine-free bu¡-
er. This behaviour has been postulated to be due to phenyl-
alanine activation of PAH causing conformational changes
that expose a hydrophobic surface, which can bind to phe-
nyl-Sepharose [8]. Signi¢cantly, phenylalanine-activated
PAH30ÿ428 did not bind strongly to phenyl-Sepharose and
was eluted in the ¢rst wash of the column (in a bu¡er con-
taining 10 mM phenylalanine and 4.8% (v/v) dimethyl form-
amide).
4. Discussion
The crystal structure of PAH1ÿ428 revealed that the N-ter-
minal sequence of the regulatory domain of the enzyme
reached into the active site, suggesting it played an autoinhi-
bitory role [16]. However, the mechanism of autoinhibition
Fig. 2. Limited chymotryptic digestion of phenylalanine-activated
PAH. A: Limited chymotryptic digestion (chymotrypsin:
PAH1ÿ428 = 1:50) of PAH1ÿ428, analysed by SDS^PAGE. Lane 1:
Proteins of known molecular weight; lane 2: PAH1ÿ428 ; lanes 3, 4
and 5: phenylalanine-activated (10 mM phenylalanine added)
PAH1ÿ428 digested with chymotrypsin for 10, 20 and 30 min, respec-
tively; lanes 6, 7 and 8: unactivated (no phenylalanine added)
PAH1ÿ428 digested with chymotrypsin for 10, 20 and 30 min, respec-
tively. PAH1ÿ428 and the catalytic fragment (PAHcat) are indicated
by arrows on the right of the gel. B: Limited chymotryptic digestion
of PAH30ÿ428, analysed as in (A). Lane 1: Proteins of known molec-
ular weight; lanes 2 and 6: PAH30ÿ428 ; lanes 3, 4 and 5: phenylala-
nine-activated PAH30ÿ428 digested with chymotrypsin for 10, 20 and
30 min, respectively; lanes 7, 8 and 9: unactivated PAH30ÿ428 di-
gested with chymotrypsin for 10, 20 and 30 min, respectively.
Table 1
Activation of PAH by phenylalaninea
Protein Treatment Cofactor
6-MePH4 BH4
speci¢c activity fold-activation speci¢c activity fold-activation
PAH1ÿ428 activated 589 4.0 176 12.5
PAH1ÿ428 not activated 148 ^ 14 ^
PAH30ÿ428 activated 480 1.9 240 1.1
PAH30ÿ428 not activated 257 ^ 229 ^
aPAH (8.6 Wg), either activated in the presence of 10 mM phenylalanine for 10 min at 25‡C, or not activated, was added last to a cuvette con-
taining the enzyme reaction mixture with 60 WM 6-MePH4 or 90 WM BH4 as the cofactor. Enzyme speci¢c activity is expressed as nmol tyro-
sine produced/min/nmol PAH subunit).
Table 2
Inhibition of phenylalanine activation of PAH by BHa4
Protein Additions PAH enzyme activity Inhibition (%)
PAH1ÿ428 none 20.6 ^
PAH1ÿ428 2.5 WM BH4 7.35 64
PAH30ÿ428 none 33.8 ^
PAH30ÿ428 2.5 WM BH4 31.8 6
aPAH (8.6 Wg), either in the presence or absence of 2.5 WM BH4,
was added last to a cuvette containing the enzyme reaction mixture
with 60 WM 6-MePH4 as the cofactor. Enzyme activity is expressed
as nmol tyrosine produced/min.
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was not clear, and no direct functional data were available to
support this hypothesis.
Here we show functional evidence supporting the regulatory
mechanism based on the structural data, suggesting the 29
amino-terminal residues of PAH are directly responsible for
the autoinhibited state of PAH, and that this sequence trans-
mits the e¡ect of phenylalanine activation through to the ac-
tive site. We deleted the N-terminal 29 amino acids from the
dimeric protein PAH1ÿ428 and expressed, puri¢ed and charac-
terised the regulatory properties of the resulting protein
PAH30ÿ428. The dimeric PAH1ÿ428 was used as the template
to avoid any complications resulting from the use of the full-
length protein which exists as a mixture of dimers and tet-
ramers. The regulatory and catalytic properties of PAH1ÿ428
are indistinguishable from the full-length protein [17,18].
In contrast to PAH1ÿ428 or full-length PAH, the PAH30ÿ428
protein was found to be constitutively active; activation by
phenylalanine was not required for enzyme activity. Consis-
tent with previous studies on human PAH [27], the e¡ect of
phenylalanine was more dramatic when the natural cofactor,
BH4, rather than the synthetic cofactor, 6-MePH4, was used
in the PAH assay. In addition, the inhibition of PAH activa-
tion by BH4 was abolished by the removal of the N-terminal
29 amino acids. PAH30ÿ428 therefore mimics phenylalanine-
activated PAH, which is not inhibited by BH4 [12]. The
changed limited proteolysis pattern generated by chymotryp-
sin digestion of PAH30ÿ428, and the low a⁄nity of PAH30ÿ428
for phenyl-Sepharose suggest that the conformational changes
generated by phenylalanine activation of PAH1ÿ428 do not
occur as e⁄ciently in the constitutively active PAH30ÿ428.
A model for the regulation of PAH enzyme activity by
phenylalanine, BH4 and phosphorylation consistent with the
available structural and functional data is shown in Fig. 3. Ei
depicts the autoinhibited state where the IARS obstructs the
active site and BH4 is bound to its regulatory site (Fig. 3, left
column). Phenylalanine binding to its activation site causes
conformational changes, during which the IARS must move
away from its position at the active site and BH4 can bind to
its catalytic site, resulting in the activated state Ea (Fig. 3,
right column). The middle column in Fig. 3 depicts an inter-
mediate inactive state with no e¡ectors bound to their regu-
latory sites (Ei*); this is the only state for which structural
information is currently available. Phosphorylation (Fig. 3,
bottom row) most likely aids the transition from Ei to Ea
by facilitating the phenylalanine-induced conformational
changes through stabilising the phenylalanine-activated form
[16].
The members of the aromatic amino acid hydroxylase fam-
ily share signi¢cant amino acid sequence and structural sim-
ilarities in their catalytic domains, but their regulatory do-
mains are less conserved. However, the basic folds of the
regulatory domains [16] as well as some aspects of the regu-
latory mechanisms may be conserved among the family mem-
bers. In TH, catecholamines form an inactive TH complex by
binding to the enzyme-bound iron. Phosphorylation of TH at
Ser-40 by cAMP-dependent protein kinase decreases the a⁄n-
ity of dopamine for the iron 300-fold [28]. In line with the
results reported here for PAH, TH lacking the N-terminal 39
amino acids was found not to be inhibited by catecholamines
[29]. Limited proteolysis studies showed that amino acids 33
to 50 on the TH sequence were less sensitive to proteolysis
when dopamine was bound to TH, and more sensitive to
proteolysis when TH was phosphorylated at Ser-40 [30].
Therefore, similarly to the IARS of PAH, the N-terminal se-
quence of TH plays an integral role in the regulation of TH
activity, acting in concert with catecholamine to form the
inactive TH, and phosphorylation produces conformational
changes that a¡ect the N-terminus and cause the dissociation
of the catecholamine^TH complex, resulting in the active en-
zyme. By contrast, it has very recently been shown that the
deletion of 15 N-terminal residues of TPH does not a¡ect the
catalytic properties of that enzyme [31]; the regulatory mech-
anisms in TPH, however, remain to be elucidated.
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